Table 2.
CD-19 CAR-T cell-based therapies in R/R B-cell NHL.
| Title | Axicabtagene Ciloleucel | Axicabtagene Ciloleucel | Tisagenlecleucel | Lisocabtagene Maraleucel |
|---|---|---|---|---|
| Clinical Trial |
NCT02348216 (ZUMA-1) |
NCT02601313 (ZUMA-2) |
NCT02445248 (JULIET) |
NCT02631044 (TRANSCEND) |
| Response Rate |
ORR = 82% CR = 54% |
ORR = 93% CR = 67% |
ORR = 59% CR = 43% |
ORR = 74% CR = 52% |
| Histological subtype (n) | DLBCL (77) tFL/PMBCL (24) |
MCL (68) | DLBCL (51) | DLBCL (40) tDLBCL (14) FL grade 3B (1) |
Abbreviations: ORR—overall response rate; CR—complete remission; DLBCL—diffuse large B-cell lymphoma; tFL—transformed follicular lymphoma; MCL—mantle cell lymphoma; tDLBCL—transformed DLBCL; R/R—relapsed/refractory. Table constructed with data from [125] and modified with latest updates.